Protalix Biotherapeutics Inc (PLX)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $257.17M
Last updated: Nov 17, 2026 at 11:05 AM ET
Protalix Biotherapeutics Inc (PLX) Financials: Revenue, Profit and Cash Flow
Protalix Biotherapeutics reported revenue of $52.74M for the fiscal year ended Dec 31, 2025, down 1.2% from the year before. That year, net income was -$6.60M with a net margin of -12.5%, operating cash flow was -$11.99M and free cash flow was -$13.63M. The quarter ended Sep 30, 2026 had revenue of $21.93M and net income of $3.96M.
Revenue and Margins
The operating margin was -10.4% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $9.20M, a compound annual rate of 21.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $52.74M | -1.2% | 48.8% | -10.4% | -12.5% |
| Dec 2024 | $53.40M | -18.5% | 54.5% | 7.3% | 5.5% |
| Dec 2023 | $65.49M | +37.5% | 64.9% | 16.0% | 12.7% |
| Dec 2022 | $47.64M | +24.2% | 58.9% | -27.3% | -31.3% |
| Dec 2021 | $38.35M | -39.0% | 57.4% | -53.4% | -71.9% |
| Dec 2020 | $62.90M | +15.0% | 82.7% | 4.3% | -10.4% |
| Dec 2019 | $54.69M | N/A | 80.1% | -19.6% | -33.4% |
| Dec 2018 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2017 | $21.08M | +129.1% | 27.7% | -163.8% | -395.9% |
| Dec 2016 | $9.20M | N/A | 8.7% | -360.5% | -319.2% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, net income rose 68.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.74M | $53.40M | $65.49M | $47.64M | $38.35M | $62.90M | $54.69M | $0 | $21.08M | $9.20M |
| Cost of revenue | $26.99M | $24.32M | $22.98M | $19.59M | $16.35M | $10.87M | $10.89M | $9.30M | $15.23M | $8.40M |
| Gross profit | $25.75M | $29.08M | $42.51M | $28.05M | $22.00M | $52.02M | $43.80M | -$9.30M | $5.85M | $801.00K |
| Research and development | $19.57M | $12.97M | $17.09M | $29.35M | $29.73M | $38.17M | $44.62M | $33.33M | $32.17M | $30.41M |
| Operating income | -$5.50M | $3.92M | $10.46M | -$13.01M | -$20.46M | $2.71M | -$10.72M | -$19.31M | -$34.52M | -$33.16M |
| Net income | -$6.60M | $2.93M | $8.31M | -$14.93M | -$27.58M | -$6.52M | -$18.28M | -$26.46M | -$83.44M | -$29.36M |
| EBITDA | -$4.14M | $5.46M | N/A | -$13.01M | N/A | N/A | N/A | N/A | N/A | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.93M | $19.90M | $33.75M | $9.12M | $17.85M | $15.66M | $10.11M | $18.22M | $17.96M | $13.47M | $3.75M | $10.49M |
| Gross profit | $14.05M | $12.13M | $29.62M | $4.50M | $9.53M | $9.79M | $1.93M | $14.33M | $9.58M | $4.02M | $1.15M | $1.63M |
| Operating income | $4.05M | $4.67M | $21.15M | -$4.66M | $2.13M | $1.17M | -$4.14M | $7.21M | $3.99M | -$2.43M | -$4.86M | -$5.62M |
| Net income | $3.96M | $3.78M | $18.32M | -$5.50M | $2.35M | $164.00K | -$3.62M | $6.49M | $3.24M | -$2.20M | -$4.59M | -$6.04M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $1.38M by $13.30M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $82.35M | $73.42M | $84.43M | $55.79M | $73.67M | $67.93M | $45.39M | $61.13M | $72.21M | $82.25M |
| Current assets | $66.67M | $60.08M | $69.93M | $44.88M | $61.67M | $55.72M | $32.48M | $52.98M | $62.65M | $71.87M |
| Cash and equivalents | $14.68M | $19.76M | $23.63M | $17.11M | $38.98M | $18.27M | $17.79M | $37.81M | $51.16M | $63.28M |
| Total liabilities | $34.12M | $30.21M | $50.87M | $66.43M | $79.70M | $94.97M | $115.71M | $114.01M | $101.67M | $92.20M |
| Short-term debt | $1.38M | $1.50M | $20.25M | $0 | $1.21M | $58.51M | $4.30M | $0 | $5.92M | $53.87M |
| Long-term debt | N/A | N/A | N/A | $28.19M | $27.89M | $0 | $50.96M | $47.97M | $46.27M | $19.34M |
| Shareholder equity | $48.23M | $43.21M | $33.57M | -$10.64M | -$6.04M | -$27.04M | -$70.32M | -$52.88M | -$29.46M | -$9.96M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $118.24M | $110.34M | $102.34M | $82.35M | $82.26M | $78.49M | $73.89M | $73.42M | $61.56M | $91.54M | $89.83M | $84.43M |
| Total liabilities | $37.69M | $38.93M | $35.11M | $34.12M | $29.36M | $28.58M | $28.68M | $30.21M | $29.13M | $62.96M | $60.04M | $50.87M |
| Cash and equivalents | $22.04M | $27.42M | $41.00M | $14.68M | $13.65M | $17.89M | $19.46M | $19.76M | $27.41M | $23.40M | $27.21M | $23.63M |
| Shareholder equity | $80.55M | $71.40M | $67.23M | $48.23M | $52.91M | $49.90M | $45.21M | $43.21M | $32.44M | $28.58M | $29.79M | $33.57M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.99M | $8.67M | -$1.32M | -$25.00M | -$10.29M | -$26.11M | -$19.36M | -$7.74M | -$9.99M | -$32.10M |
| Capital expenditures | $1.64M | $1.28M | $1.15M | $628.00K | $1.46M | $655.00K | $627.00K | $686.00K | $971.00K | $849.00K |
| Free cash flow | -$13.63M | $7.39M | -$2.47M | -$25.63M | -$11.74M | -$26.76M | -$19.98M | -$8.43M | -$10.96M | -$32.95M |
| Investing cash flow | -$2.37M | $4.22M | -$16.71M | -$5.04M | $18.92M | -$19.95M | -$883.00K | -$591.00K | -$1.12M | -$967.00K |
| Financing cash flow | $9.33M | -$16.79M | $24.67M | $8.24M | $12.08M | $46.47M | $0 | -$4.75M | -$1.42M | $19.70M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.90M | -$10.40M | $22.02M | $2.03M | -$3.73M | -$5.23M | -$5.06M | $3.99M | $4.11M | -$3.61M | $4.19M | $3.60M |
| Capital expenditures | $737.00K | $593.00K | $761.00K | $403.00K | $498.00K | $431.00K | $306.00K | $425.00K | $87.00K | $172.00K | $598.00K | $250.00K |
| Free cash flow | $3.17M | -$10.99M | $21.26M | $1.63M | -$4.23M | -$5.66M | -$5.36M | $3.57M | $4.02M | -$3.78M | $3.59M | $3.35M |
Frequently Asked Questions About PLX
What is Protalix Biotherapeutics' annual revenue?
Protalix Biotherapeutics reported revenue of $52.74M for the fiscal year ended Dec 31, 2025.
How fast is Protalix Biotherapeutics' revenue growing?
Revenue was down 1.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 3.5%.
Is Protalix Biotherapeutics profitable?
No. Protalix Biotherapeutics reported net income of -$6.60M for the fiscal year ended Dec 31, 2025, with a net margin of -12.5%.
How much free cash flow does PLX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$11.99M minus capital expenditures of $1.64M produced free cash flow of -$13.63M.
How much debt does Protalix Biotherapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $1.38M and cash and equivalents of $14.68M.
PLX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors